Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Yangyun Huang"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-16 (2024)
Abstract CRTAC1, one of the pyroptosis-related genes, has been identified as a protective factor in certain kinds of cancer, such as gastric adenocarcinoma and bladder cancer. The study aimed to investigate the role of CRTAC1 in lung adenocarcinoma (
Externí odkaz:
https://doaj.org/article/3350c4a1682e4ead8b3339db4a154c80
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-14 (2021)
Abstract Background Cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acid to epoxyeicosatrienoic acids (EETs), which exert anti-inflammatory, anti-apoptotic, pro-proliferative, and antioxidant effects on the cardiovascular system. How
Externí odkaz:
https://doaj.org/article/2d97708cbc7f420e822375acdc920453
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 5, Pp 1278-1287 (2021)
Background Programmed cell death protein 1 (PD-1) inhibitors are the first-line treatment for advanced non-small-cell lung cancer (NSCLC) patients. However, their efficacy in metastatic NSCLC patients remains controversial. Aim of the study The aim o
Externí odkaz:
https://doaj.org/article/9ca03693ba464261906a620705690b6c
Autor:
Wenshu Chen, Guanying Zheng, Jianyuan Huang, Lihuan Zhu, Wujin Li, Tianxing Guo, Yangyun Huang, Xiaojie Pan
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Metastasis and disease refractoriness remain as major challenges for non-small cell lung cancer (NSCLC) treatment and understanding the underlying molecular mechanisms is of scientific and clinical value. Therefore, in this study,
Externí odkaz:
https://doaj.org/article/903c20dba4e14e2487a81d601202cecf
Publikováno v:
Cancer Cell International, Vol 20, Iss 1, Pp 1-14 (2020)
Abstract Background Lung adenocarcinoma has surpassed lung squamous cell carcinoma as the most common type of non-small cell lung cancer. In this study, we had tested the biological role of TRIM2 in lung adenocarcinoma. Methods TRIM2 abundance in cli
Externí odkaz:
https://doaj.org/article/9829ba10787446f3abb4cf6aaeeff63f
Autor:
Wenbao Lin, Jinlan Lin, Yangyun Huang, Lihuang Zhu, Wujin Li, Lilan Zhao, Xiaojie Pan, Tianxing Guo
Publikováno v:
Journal of Gastrointestinal Oncology. 13:2758-2768
Background Pembrolizumab has been approved by the Food and Drug Administration (FDA) for the first-line treatment of locally advanced or metastatic esophageal cancer. This study investigated the efficacy and safety of pembrolizumab combined with pacl
Autor:
Tianxing Guo, Zhenlong Zhang, Lihuan Zhu, Wenshu Chen, Yun Ding, Wujin Li, Yangyun Huang, Jianyuan Huang, Xiaojie Pan
Publikováno v:
Cancer Biology & Therapy
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Up until now, cancer refractoriness and distal organ metastatic disease remain as major obstacles for oncologists to achieve satisfactory therapeutic effects for lung adenocarcinoma patients. Previous studies indicated that TRIM55, which participates
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-14 (2021)
Respiratory Research
Respiratory Research
Background Cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acid to epoxyeicosatrienoic acids (EETs), which exert anti-inflammatory, anti-apoptotic, pro-proliferative, and antioxidant effects on the cardiovascular system. However, the
Autor:
Lihuan Zhu, Yangyun Huang, Wujing Li, Dongsheng Zhou, Wenshu Chen, Xiaojie Pan, Tianxing Guo, Yun Ding, Jianyuan Huang
Publikováno v:
Journal of Cancer
Background: Lung cancer is a malignant tumor in mammary gland epithelium with high morbidity and mortality among women worldwide. Long noncoding RNA GAS5 (GAS5) has been proved to be closely related with tumor progression. However, the influence of G
Autor:
Long Chen, Tianxing Guo, Yun Ding, Wujin Li, Rongjia Lin, Lihuan Zhu, Yangyun Huang, jinlan Lin, Ji-guang Zhang, Xiaojie Pan
Publikováno v:
J Thorac Dis
Background Immune checkpoint inhibitors (ICIs) provided a paradigm shift for advanced non-small cell lung cancer (NSCLC) treatment and improved the clinical prognosis of such patients. Pembrolizumab is a humanized anti-programmed death cell protein 1